Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAL as Adjuvant Therapy in HCC
NCT05213637Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2018
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Expanded Activated Lymphocytes in hepatocellular carcinoma (HCC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
Expanded Activated Lymphocytes
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05213637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213637.